Polycystic ovary syndrome
Conditions
Interventions
control group:Treatment with clomiphene citrate: Initiate on day 5 of menstruation or withdrawal bleeding, at a dose of 50-100 mg daily for 5-10 consecutive days until ovulation occurs.
wenshen group:Treatment with clomiphene citrate combined with a kidney-warming and blood-nourishing formula: Begin clomiphene citrate on day 5 of menstruation or withdrawal bleeding, taking 50-100mg o
Stimulation Group:Treatment with CC plus endometrial microstimulation: During the early follicular phase (days 2-5 of menstruation), perform microstimulation of the endometrium using a single-use intr
joint group:Combined treatment with CC + Kidney-Warming and Blood-Nourishing Formula and Endometrial Microstimulation: Perform microstimulation of the endometrium using a single-use intrauterine tissu
Sponsors
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Individuals meeting both Traditional Chinese Medicine syndrome differentiation criteria and Western medical diagnostic standards; (2) Individuals aged 18 to 40 years (inclusive of 18 and 40 years) with a desire to conceive; (3) Patients willing to undergo trial interventions and control measures, who sign an informed consent form and are available for follow-up.
Exclusion criteria
Exclusion criteria: (1) Individuals who do not meet Western medical diagnostic criteria or Traditional Chinese Medicine (TCM) pattern differentiation criteria. (2) Women under 18 years of age or over 40 years of age. (3) Individuals without a desire for pregnancy. (4) Those with a history of ineffective ovulation induction using clomiphene citrate. (5) Patients with concomitant primary diseases of the liver, kidneys, cardiovascular system, cerebrovascular system, hematopoietic system, or psychiatric disorders. (6) Patients with allergic constitutions, such as those with a history of allergy to two or more drugs or foods; or those with known allergy to any component of this drug. (7) Patients meeting inclusion criteria but failing to take medication as prescribed, rendering efficacy assessment impossible or incomplete. (8) Patients currently participating in other drug clinical trials. (9) Patients unable to cooperate with treatment or attend follow-up visits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ovulation status;Endometrial receptivity;Six Endocrine Panel;Fasting blood glucose;Fasting insulin;Coagulation parameters;Traditional Chinese Medicine Syndrome Score; | — |
Countries
China
Contacts
Public ContactXin Mingwei
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Outcome results
None listed